Actively Recruiting
Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).
Led by Andrés José Maria Ferreri · Updated on 2026-02-03
25
Participants Needed
1
Research Sites
56 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Retrospective, multicenter observational study to evaluate the response to treatment with Mosunetuzumab in relapsed/refractory Follicular Lymphoma (FL) after at least three lines of therapy, within the Compassionate Use Program (CUP).
CONDITIONS
Official Title
Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients (over 18 years) with follicular non-Hodgkin's lymphoma
- Have undergone at least two lines of therapy
- Treated with Mosunetuzumab under a compassionate use program
- Signed informed consent for treatment
You will not qualify if you...
- Under 18 years old
- Diagnosed with other types of cancer or lymphoma
- Not eligible for the Mosunetuzumab compassionate use program
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCCS Ospedale San Raffaele
Milan, Italy, 20132
Actively Recruiting
Research Team
A
Andres JM Ferreri, Prof
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here